Fecal microbiota transplantation eliminates Clostridium difficile in a murine model of relapsing disease

Infection and Immunity

Volumn 83, Issue 10, 2015, Pages 3838-3846

  Seekatz, Anna M ^a   Theriot, Casey M ^a,c   Molloy, Caitlyn T ^a   Wozniak, Katherine L ^a   Bergin, Ingrid L ^b   Young, Vincent B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CLINDAMYCIN; CYTOTOXIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL SPORE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; INTESTINE FLORA; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RELAPSE; RISK REDUCTION; SINGLE DRUG DOSE; TRANSPLANTATION; ANIMAL; BACTERIUM; C57BL MOUSE; CHRONIC DISEASE; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; FECES; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; RECURRENT DISEASE;

ANIMALS; BACTERIA; CHRONIC DISEASE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROBIOTA; RECURRENCE;

EID: 84944474480     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00459-15     Document Type: Article

References (35)

1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825-834. http://dx.doi.org/10.1056/NEJMoa1408913.
2. Musher DM, Aslam S, Logan N, Nallcheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586-1590. http://dx.doi.org/10.1086/430311.
3. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8:17-26. http://dx.doi.org/10.1038/nrgastro.2010.190.
4. van der Waaji D. 1989. The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile. Annu Rev Microbiol 43:69-87. http://dx.doi.org/10.1146/annurev.mi.43.100189.000441.
5. Theriot CM, Koenigsknecht MJ, Carlson PE, Jr, Hatton GE, Nelson AM, Li B, Huffnagle GBZLJ, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114. http://dx.doi.org/10.1038/ncomms4114.
6. Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, AronoffDM, Schloss PD. 2014. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. mBio 5:e01021-14. http://dx.doi.org/10.1128/mBio.01021-14.
7. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. 2013. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 51:2884-2892. http://dx.doi.org/10.1128/JCM.00845-13.
8. Bassis CM, Theriot CM, Young VB. 2014. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother 58:2767-2774. http://dx.doi.org/10.1128/AAC.02262-13.
9. Owens RC, Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S19-S31. http://dx.doi.org/10.1086/521859.
10. Seekatz AM, Young VB. 2014. Clostridium difficile and the microbiota. J Clin Invest 124:4182-4189. http://dx.doi.org/10.1172/JCI72336.
11. Theriot CM, Schumacher CA, Bassis CM, Seekatz AM, Young VB. 2014. The effects of tigecycline and vancomycin administration on established Clostridium difficile infection. Antimicrob Agents Chemother 59:1596-1604. http://dx.doi.org/10.1128/AAC.04296-14.
12. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435-438. http://dx.doi.org/10.1086/525047.
13. Gough E, Shaikh H, Manges AR. 2011. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994-1002. http://dx.doi.org/10.1093/cid/cir632.
14. Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB. 2014. Recovery of the gut microbiome following fecal microbiota transplantation. mBio 5:e00893-14. http://dx.doi.org/10.1128/mBio.00893-14.
15. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. 2013. High-throughputDNAsequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4:125-135. http://dx.doi.org/10.4161/gmic.23571.
16. Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke FW. 2013. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 8:e81330. http://dx.doi.org/10.1371/journal.pone.0081330.
17. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, AronoffDM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326-334. http://dx.doi.org/10.4161/gmic.19142.
18. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2:145-158. http://dx.doi.org/10.4161/gmic.2.3.16333.
19. Koenigsknecht MJ, Theriot CM, Bergin IL, Schumacher CA, Schloss PD, Young VB. 2015. Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect Immun 83:934-941. http://dx.doi.org/10.1128/IAI.02768-14.
20. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79:5112-5120. http://dx.doi.org/10.1128/AEM.01043-13.
21. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75:7537-7541. http://dx.doi.org/10.1128/AEM.01541-09.
22. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, Glockner FO. 2007. SILVA: a comprehensive online resource for quality checked and aligned rRNA sequence data compatible with ARB. Nucleic Acids Res 35:7188-7196. http://dx.doi.org/10.1093/nar/gkm864.
23. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. 2011. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27:2194-2200. http://dx.doi.org/10.1093/bioinformatics/btr381.
24. Wang Q, Garrity GM, Tiedje JM, Cole JR. 2007. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73:5261-5267. http://dx.doi.org/10.1128/AEM.00062-07.
25. Yue JC, Clayton MK. 2005. A similarity measure based on species proportions. Commun Stat Theory Methods 34:2123-2131. http://dx.doi.org/10.1080/STA-200066418.
26. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara RB, Simpson GL, Solymos P, Stevens MH, Wagner H. 2013. Community Ecology Package, v2.0-10. https://cran.r-project.org/.
27. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Liaw WH, Lumley T, Maechler M, Magnusson A, Moeller S, Schwartz M, Venables B. 2013. gplots: various R programming tools for plotting data (v2.12.1). http://cran.r-project.org/web/packages/gplots/gplots.pdf.
28. Excoffier L, Smouse PE, Quattro JM. 1992. Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 131:479-491.
29. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77:3661-3669. http://dx.doi.org/10.1128/IAI.00558-09.
30. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
31. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80:62-73. http://dx.doi.org/10.1128/IAI.05496-11.
32. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
33. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205-208. http://dx.doi.org/10.1038/nature13828.
34. Rao K, Young VB. 2015. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 29:109-122. http://dx.doi.org/10.1016/j.idc.2014.11.009.
35. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8:e1002995. http://dx.doi.org/10.1371/journal.ppat.1002995.